FDA cracks down on fake weight-loss drugs as patients lose access to cheaper GLP-1 alternatives
GLP-1 weight-loss drugs are now the center of a federal crackdown. The FDA has begun seizing counterfeit semaglutide and tirzepatide products from the U.S. supply chain. Some vials contained bacterial contamination. Others were mislabeled or chemically altered. The agency confirmed …